DMD

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Drug Metabolism and Disposition Fast Forward
First published on March 24, 2008; DOI: 10.1124/dmd.108.021089


0090-9556/08/3607-1438-1443$20.00
DMD 36:1438-1443, 2008

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dmd.108.021089v1
36/7/1438    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Makino, T.
Right arrow Articles by Mizukami, H.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Makino, T.
Right arrow Articles by Mizukami, H.

Down-Regulation of a Hepatic Transporter Multidrug Resistance-Associated Protein 2 Is Involved in Alteration of Pharmacokinetics of Glycyrrhizin and Its Metabolites in a Rat Model of Chronic Liver Injury

Toshiaki Makino, Nobuhiro Ohtake, Akito Watanabe, Naoko Tsuchiya, Sachiko Imamura, Seiichi Iizuka, Makoto Inoue, and Hajime Mizukami

Department of Pharmacognosy, Graduate School of Pharmaceutical Science, Nagoya City University, Nagoya, Japan (T.M., A.W., H.M.); Tsumura Research Laboratories, Tsumura Co. Ltd., Ami-machi, Ibaraki, Japan (N.O., N.T., S.Im., S.Ii.); and Laboratory of Medicinal Resources, School of Pharmacy, Aichi Gakuin University, Nagoya, Japan (M.I.)

Glycyrrhizin (GL) has been used to treat chronic hepatitis in Japan and Europe. It is thought to induce pseudoaldosteronism via inhibition of type 2 11β-hydroxysteroid dehydrogenase (11β-HSD2) by glycyrrhetinic acid (GA), a major metabolite of GL. A previous clinical study suggested that 3-monoglucuronyl-glycyrrhetinic acid (3MGA), another metabolite of GL, might play a more important role in the pathogenesis of pseudoaldosteronism. The present study evaluates the pharmacokinetics of GL and its metabolites in rats with chronic liver injury induced by a choline-deficient L-amino acid-defined (CDAA) diet to clarify the relationship between 3MGA and pseudoaldosteronism. In rats fed a CDAA diet, plasma concentrations and urinary eliminations of GL and 3MGA were markedly higher than in the rats fed the control diet; the plasma concentration of GA was unaffected when GL was orally administered. Immunohistochemical analysis revealed the suppression of levels of multidrug resistance-associated protein (Mrp) 2 and its localization in the hepatic tissue of rats fed a CDAA diet. When 3MGA was i.v. injected in rats fed a CDAA diet or injected in Mrp2-dysfunctional Eisai hyperbilirubinemic rats, plasma concentrations of 3MGA were higher, and biliary excretion of 3MGA was lower than in each control group. The results suggested that 3MGA would be excreted to bile via hepatic Mrp2 and that its dysfunction would reduce 3MGA clearance. 3MGA accumulated by liver fibrosis resulted in the increased excretion through renal tubule and might be strongly related to the pathogenesis of pseudoaldosteronism because 11β-HSD2 is expressed in renal tubular epithelial cells.


Address correspondence to: Dr. Toshiaki Makino, Department of Pharmacognosy, Graduate School of Pharmaceutical Science, Nagoya City University, 3-1 Mizuho-ku, Nagoya 467-8603, Japan. E-mail: makino{at}phar.nagoya-cu.ac.jp







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics.